Haemonetics Corporation (HAE) Earning Somewhat Favorable News Coverage, Study Shows
News coverage about Haemonetics Corporation (NYSE:HAE) has trended somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Haemonetics Corporation earned a news impact score of 0.01 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.3076442748506 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- North America Apheresis Market to reach to reach USD 0.94 billion by 2021, Says MDF Research (emailwire.com)
- Explore North American apheresis market estimated to grow at a CAGR of 10.87% during 2016 to 2021 (whatech.com)
- Global Plasmapheresis Machines Market 2017 Haemonetics Corporation, Fenwal … (medgadget.com)
- Haemonetics : Appoints David J. Wilson Plasma Business Unit President (4-traders.com)
- Haemonetics Appoints David J. Wilson Plasma Business Unit President (finance.yahoo.com)
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, August 29th. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target for the company in a report on Tuesday, August 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 price target on shares of Haemonetics Corporation in a report on Thursday, July 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. Haemonetics Corporation presently has an average rating of “Hold” and an average target price of $40.71.
Haemonetics Corporation (NYSE HAE) opened at 42.29 on Friday. The company has a 50-day moving average of $42.14 and a 200 day moving average of $40.82. The company has a market cap of $2.22 billion, a P/E ratio of 549.22 and a beta of 0.89. Haemonetics Corporation has a 52 week low of $32.76 and a 52 week high of $43.77.
Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business had revenue of $211.00 million during the quarter, compared to analyst estimates of $211.29 million. During the same period in the previous year, the business posted $0.25 earnings per share. Haemonetics Corporation’s revenue for the quarter was up .5% on a year-over-year basis. On average, equities analysts forecast that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.
Haemonetics Corporation Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Stock Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related stocks with our FREE daily email newsletter.